ACME INTL HLDGS (01870): Termination of the placement of new shares under the general mandate.
Yimei International Holdings (01870) announced that it plans to place up to 50 million shares. Based on market conditions, the company and the placing agent have mutually agreed to terminate the placing agreement, effective immediately. A termination deed was signed on August 5, 2026, which thereby causes the placing agreement to be immediately terminated and no longer valid. Notwithstanding any provisions to the contrary in the placing agreement, all parties must absolutely release and discharge each other from all past, present, and future duties, obligations, and liabilities under the placing agreement.
ACME INTL HLDGS (01870) announced that it plans to allocate up to 50 million shares. Based on market conditions, the company and the placement agent have mutually agreed to terminate the placement agreement, effective immediately. A termination deed was executed on August 5, 2026, and accordingly, the placement agreement will be immediately terminated and shall no longer be in effect. Furthermore, despite any provisions in the placement agreement to the contrary, all parties shall absolutely release and discharge each other from all past, present, and future duties, obligations, and liabilities under the placement agreement.
The directors believe that the termination of the placement agreement and the proposed placement thereunder will not have a significant adverse impact on the Group's business operations and financial position. After considering the Group's future development and market conditions, the company may consider conducting further fundraising activities.
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





